These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

151 related items for PubMed ID: 6775530

  • 21. Presence of activator proteins for the enzymatic degradation of glucosylceramide in several human tissues.
    Vaccaro AM, Ciaffoni F, Mandara I, Suzuki K.
    Clin Chim Acta; 1988 Mar 15; 172(2-3):323-34. PubMed ID: 3370844
    [Abstract] [Full Text] [Related]

  • 22. A high throughput glucocerebrosidase assay using the natural substrate glucosylceramide.
    Motabar O, Goldin E, Leister W, Liu K, Southall N, Huang W, Marugan JJ, Sidransky E, Zheng W.
    Anal Bioanal Chem; 2012 Jan 15; 402(2):731-9. PubMed ID: 22033823
    [Abstract] [Full Text] [Related]

  • 23. Activation of membrane-bound glucosylceramide: beta-glucosidase in fibroblasts cultured from normal and glucosylceramidotic human skin.
    Mueller OT, Rosenberg A.
    J Biol Chem; 1979 May 10; 254(9):3521-5. PubMed ID: 429368
    [No Abstract] [Full Text] [Related]

  • 24. Analysis of glucocerebrosidase activity using N-(1-[14C]hexanoyl)-D-erythroglucosylsphingosine demonstrates a correlation between levels of residual enzyme activity and the type of Gaucher disease.
    Meivar-Levy I, Horowitz M, Futerman AH.
    Biochem J; 1994 Oct 15; 303 ( Pt 2)(Pt 2):377-82. PubMed ID: 7980395
    [Abstract] [Full Text] [Related]

  • 25. Glucocerebroside storage in normal monocyte cultures.
    Hardy B, Teitelman-Weissman B, Chazan S, Neri A.
    Biomed Pharmacother; 1987 Oct 15; 41(1):40-4. PubMed ID: 3607254
    [Abstract] [Full Text] [Related]

  • 26. Properties of beta-glucosidase in cultured skin fibroblasts from controls and patients with Gaucher disease.
    Turner BM, Hirschhorn K.
    Am J Hum Genet; 1978 Jul 15; 30(4):346-58. PubMed ID: 102189
    [Abstract] [Full Text] [Related]

  • 27. Deficient activity of glucocerebrosidase in urine from patients with type 1 Gaucher disease.
    Aerts JM, Donker-Koopman WE, Koot M, Barranger JA, Tager JM, Schram AW.
    Clin Chim Acta; 1986 Jul 30; 158(2):155-63. PubMed ID: 2943536
    [Abstract] [Full Text] [Related]

  • 28. Increased glucocerebrosidase (GBA) 2 activity in GBA1 deficient mice brains and in Gaucher leucocytes.
    Burke DG, Rahim AA, Waddington SN, Karlsson S, Enquist I, Bhatia K, Mehta A, Vellodi A, Heales S.
    J Inherit Metab Dis; 2013 Sep 30; 36(5):869-72. PubMed ID: 23151684
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Gaucher disease: genetic heterogeneity within and among the subtypes detected by immunoblotting.
    Fabbro D, Desnick RJ, Grabowski GA.
    Am J Hum Genet; 1987 Jan 30; 40(1):15-31. PubMed ID: 3812484
    [Abstract] [Full Text] [Related]

  • 31. Comparative study on glucocerebrosidase in spleens from patients with Gaucher disease.
    Aerts JM, Donker-Koopman WE, Brul S, Van Weely S, Sa Miranda MC, Barranger JA, Tager JM, Schram AW.
    Biochem J; 1990 Jul 01; 269(1):93-100. PubMed ID: 2198026
    [Abstract] [Full Text] [Related]

  • 32. Soluble and membranous neutral beta-glucosidases.
    Ben-Yoseph Y, Nadler HL.
    Prog Clin Biol Res; 1982 Jul 01; 95():465-80. PubMed ID: 6812082
    [Abstract] [Full Text] [Related]

  • 33. Gaucher type I (Ashkenazi) disease: a new method for heterozygote detection using a novel fluorescent natural substrate.
    Grabowski GA, Dinur T, Gatt S, Desnick RJ.
    Clin Chim Acta; 1982 Sep 01; 124(1):123-35. PubMed ID: 6889929
    [Abstract] [Full Text] [Related]

  • 34. Assay of the beta-glucosidase activity with natural labelled and artificial substrates in leukocytes from homozygotes and heterozygotes with the Norrbottnian type (Type 3) of Gaucher disease.
    Svennerholm L, Håkansson G, Dreborg S.
    Clin Chim Acta; 1980 Sep 25; 106(2):183-93. PubMed ID: 6773705
    [Abstract] [Full Text] [Related]

  • 35. Gaucher's disease II. Studies on the kinetics of beta-glucosidase and the effects of sodium taurocholate in normal and Gaucher tissues.
    Choy FY, Davidson RG.
    Pediatr Res; 1980 Jan 25; 14(1):54-9. PubMed ID: 6767218
    [Abstract] [Full Text] [Related]

  • 36. Multiple glycosidase deficiencies in a case of juvenile (type 3) Gaucher disease.
    Chiao YB, Hoyson GM, Peters SP, Lee RE, Diven W, Murphy JV, Glew RH.
    Proc Natl Acad Sci U S A; 1978 May 25; 75(5):2448-52. PubMed ID: 27787
    [Abstract] [Full Text] [Related]

  • 37. Inhibitors and stimulators of glucocerebroside metabolism.
    Radin NS.
    Prog Clin Biol Res; 1982 May 25; 95():357-83. PubMed ID: 6214799
    [No Abstract] [Full Text] [Related]

  • 38. Gaucher disease: isolation and comparison of normal and mutant glucocerebrosidase from human spleen tissue.
    Pentchev PG, Brady RO, Blair HE, Britton DE, Sorrell SH.
    Proc Natl Acad Sci U S A; 1978 Aug 25; 75(8):3970-3. PubMed ID: 29293
    [Abstract] [Full Text] [Related]

  • 39. Role of pH in determining the cell-type-specific residual activity of glucocerebrosidase in type 1 Gaucher disease.
    van Weely S, van den Berg M, Barranger JA, Sa Miranda MC, Tager JM, Aerts JM.
    J Clin Invest; 1993 Mar 25; 91(3):1167-75. PubMed ID: 8450045
    [Abstract] [Full Text] [Related]

  • 40. Cross-reacting material in Gaucher disease fibroblasts.
    Beutler E, Kuhl W, Sorge J.
    Proc Natl Acad Sci U S A; 1984 Oct 25; 81(20):6506-10. PubMed ID: 6593712
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.